Related Experiment Video
Updated: May 4, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Optimizing statin treatment for primary prevention of coronary artery disease
Rodney A Hayward1, Harlan M Krumholz, Donna M Zulman
1University of Michigan and Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA. rhayward@umich.edu
Background:
Although treating to lipid targets ("treat to target") is widely recommended for coronary artery disease (CAD) prevention, some have advocated administering fixed doses of statins based on a person's estimated net benefit ("tailored treatment").
Objective:
To examine how a tailored treatment approach to statin therapy compares with a treat-to-target approach.
Design:
Simulated model of population-level effects of treat-to-target and tailored treatment approaches to statin therapy.
Data Sources:
Statin trials from 1994 to 2009 and nationally representative CAD risk factor data.
Target Population:
U.S. persons aged 30 to 75 years with no history of myocardial infarction.
Time Horizon:
Lifetime effects of 5 years of treatment.
Perspective:
Societal and patient.
Intervention:
Tailored treatment based on a person's 5-year CAD risk (simvastatin, 40 mg, for 5% to 15% CAD risk and atorvastatin, 40 mg, for CAD risk >15%) versus treat-to-target approaches that escalate statin dose per National Cholesterol Education Program [NCEP] III guidelines (including an intensive approach that advances treatment whenever intensification is optional by NCEP III criteria).
Outcome Measures:
Quality-adjusted life-years (QALYs).
Results Of Base-Case Analysis:
Compared with the standard NCEP III approach, the intensive NCEP III approach treated 15 million more persons and saved 570,000 more QALYs over 5 years. The tailored strategy treated a similar number of persons, as did the intensive NCEP III approach, but saved 500,000 more QALYs and treated fewer persons with high-dose statins.
Results Of Sensitivity Analysis:
No circumstances were found in which a treat-to-target approach was preferable to tailored treatment.
Limitation:
Model assumptions were based on available clinical data, which included few persons 75 years or older.
Conclusion:
A tailored treatment strategy prevents more CAD events while treating fewer persons with high-dose statins than low-density lipoprotein cholesterol-based target approaches. Results were robust, even with assumptions favoring a treat-to-target approach.
Primary Funding Source:
Department of Veteran Affairs Health Services Research & Development Service's Quality Enhancement Research Initiative.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care